NA-921™is a small molecule drug that is in Phase 2/3 clinical trials for the treatment of Rett Syndrome.
How does NA-9211™ work? NA-921 can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:
* NA-921™ exhibits neuroprotection
* NA-921 exhibits neurogenesis, i.e. ability to generate new neurons
* It has great bioavailability in the body
* It is very safe, with no toxicity observed
* It is available in oral formulation: convenient for patient to take one capsule of 30 mg per day per day.
The Phase 3 clinical trials of NA-921 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
View a selected list of PUBLICATIONS and PRESENTATIONS at CONFERENCES
For further information about our products, please contact us. Contact us